Navigation Links
Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer
Date:8/22/2014

LA JOLLA, Cali., Aug. 22, 2014 /PRNewswire/ -- Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer.

When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according to Louise T. Chow, Ph.D. and Thomas Broker, Ph.D., who presented the findings at the Seattle conference. The National Institute of Allergy and Infectious Diseases in the National Institutes of Health funded Chow's work at the University of Alabama, Birmingham.

"HTI-1968 is potent and selective, inhibiting the growth of these high-risk HPV types. Dr. Chow's findings, though early stage, offer hope to millions of women infected by one of these high-risk HPV types, including two that are responsible for 70 percent of cervical cancer cases," said Hera Therapeutics CEO Karl Hostetler, M.D.. Currently surgery is the only therapy available to women who have persistent infection with these types of HPV and show signs of abnormal cells.

Hera Therapeutics is developing a topical, non-surgical approach to treat HPV, which could alter the standard of care while preserving structural integrity of the cervix.

Approximately 96 million people worldwide, men and women, are infected with HPV-16 or HPV-18, according to the Centers for Disease Control. Almost 4,000 women in the U.S. die from invasive cervical cancer each year, according to the CDC.

While cervical cancer vaccines prevent infection from the disease, they are not approved by the FDA for marketing to people over 26-years-old and have not demonstrated efficacy in people already infected with the HPV virus.

About Hera Therapeutics Inc.

Using a new medicinal chemistry platform, Hera Therapeutics Inc. is focused on the research, development and commercialization of direct acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV and animal retroviruses.

Hera Therapeutics was founded in 2012 by Karl Hostetler, M.D., a professor emeritus at University of California, San Diego, who was previously a founder of three biotech companies, including Chimerix, Triangle Pharmaceuticals and Vical.


'/>"/>
SOURCE Hera Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
2. Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite
3. Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting
4. Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
5. FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
6. TRU-D Tested in Most Comprehensive UV Disinfection Study to Date
7. Major Clinical Study Supports NIPT As First Line Screening Test For All Pregnant Women
8. R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
9. Study: 1 out of 5 adult orthopaedic trauma patients sought additional providers for narcotic prescriptions
10. Study Helps Medical Education Leaders Navigate the New Regulatory and Financial Landscape
11. BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2019)... ... 2019 , ... A leading global health expert urged new Western University of ... health care successes and builds on them to make better lives for all the ... health at the University of Washington and Institute Director of the Institute for Health ...
(Date:5/22/2019)... ... 2019 , ... CBDNhance, a new player in the rapidly-growing ... designed to increase the benefits of CBD, especially for people seeking pain relief ... other natural ingredients that have been shown to help with CBD absorption and ...
(Date:5/22/2019)... ... May 22, 2019 , ... Americans can save more money on ... by PharmacyChecker.com which compared prices on the top-selling generic drugs. Eighty-eight percent of the ... medications; however, are far lower at Canadian and other international online pharmacies ...
Breaking Medicine Technology:
(Date:5/23/2019)... ... May 23, 2019 , ... In the U.S. in ... 1,092 embryo transfer procedures, the last step in the in vitro fertilization (IVF) process. ... five years earlier.[1] Dr. Mark P. Trolice, Director of Fertility CARE: The IVF ...
(Date:5/23/2019)... ... , ... Dr. Earl Stephenson, board-certified Face Expert representing the ... Network, well known for their exclusivity, and luxurious lifestyle, is privileged to present ... Haute Living partnership. , Haute Beauty offers a prominent collective of leading doctors ...
(Date:5/23/2019)... ... ... years after losing her daughter to injuries sustained during an stone-throwing attack in the West ... Sheba Medical Center, Tel HaShomer . The baby was born on the same birth date ... , “Just as we live with our loss 24/7, we are choosing life and continue ...
(Date:5/23/2019)... ... 2019 , ... Summit BHC (Summit), a leading provider of ... center, Bel Aire Recovery Center. Located in the suburbs of Wichita, Kansas, the ... is located in the natural landscape of the beautiful Kansas prairie. , Residential ...
(Date:5/23/2019)... ... 2019 , ... Join Dr. Ashok Srivastava, CEO & CMO at ClinFomatrix and ... at OmniComm Systems, Inc. , in a live webinar on Tuesday, ... benefits of visual patient profiles. Together, the two speakers bring years of experience in ...
Breaking Medicine News(10 mins):